Skip to main content
Premium Trial:

Request an Annual Quote

Ohio State University's Pathology Lab to Use GenomOncology's Workbench for NGS Cancer Panels

Premium

NEW YORK (GenomeWeb) – GenomOncology said this week that the pathology department at Ohio State University's college of medicine is using the GO Clinical Workbench to support its next-generation sequencing-based cancer panels.

"The GO Clinical Workbench has helped us reduce the time to develop a clinically actionable report from half a day to less than an hour," Pamela Groen, a laboratory manager at Ohio State, said in a statement.

GenomOncology's software enables molecular pathology labs analyze tumor profiles and generate actionable clinical report. The platform is installed within institutions' firewalls and is configured to each lab's specific needs including integration with laboratory systems, setting up of quality control and annotation parameters, and custom design clinical reports.

The system is also being used at CompanionDx and Cleveland's University Hospitals.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.